Clean TeQ Water (ASX: CNQ) PHOSPHIX plant beats phosphate target in first European commercial deployment

Clean TeQ Water Limited (ASX: CNQ) has completed commissioning and contractual performance testing of its first full-scale commercial PHOSPHIX phosphate removal plant in Europe, delivered with recycling and resource recovery company Enva in Ireland. The plant treated industrial wastewater from a multinational pharmaceutical manufacturer and achieved phosphate concentrations below 0.1 mg/L P-PO4, more than ten times better than the contractual requirement of 1.0 mg/L. It also exceeded its contracted hydraulic throughput while meeting specifications for pH, total nitrogen and chemical oxygen demand. The achievement moves PHOSPHIX beyond laboratory development and pilot testing into commercial operation, although the longer-term value for Clean TeQ Water will depend on whether the reference plant accelerates new orders, supports attractive project margins and creates recurring revenue.

Why does Clean TeQ Water’s first commercial PHOSPHIX reference plant matter more than another successful pilot?

For emerging industrial technologies, the distance between a successful pilot and an accepted commercial system can be wider than the engineering challenge itself. Large pharmaceutical, chemical, food processing and municipal water customers are generally reluctant to become the first operator of an unfamiliar treatment technology, particularly when failure could interrupt production, breach discharge limits or create an environmental liability.

The Ireland project addresses that procurement barrier. Prospective customers can now evaluate a full-scale installation operating under variable industrial wastewater conditions rather than relying exclusively on laboratory data, pilot campaigns or theoretical process models. This distinction matters because PHOSPHIX is being marketed not simply as a method for lowering phosphate concentrations, but as an alternative to conventional chemical dosing systems that may generate substantial volumes of ferric or alum-based sludge.

The plant is designed for approximately 99% water recovery and does not produce a liquid brine waste stream. Instead, phosphate is recovered as a solid hydroxyapatite by-product, which can be handled in a smaller volume and may have potential for beneficial reuse. These characteristics could offer customers a combination of compliance, lower waste handling requirements and improved resource recovery, but those benefits will ultimately need to be confirmed through sustained operating performance and transparent lifecycle economics.

The original contract, announced in November 2024, was valued at approximately €7 million, equivalent at the time to more than A$11 million. That made the project commercially significant relative to Clean TeQ Water’s size and followed laboratory testing and an on-site pilot programme with the pharmaceutical customer.

What does the ten-day Ireland performance test reveal about PHOSPHIX’s industrial readiness?

The contractual test was conducted continuously for ten days during June 2026, twice the originally planned five-day period. Clean TeQ Water and Enva agreed to extend the test to accommodate changes in wastewater flow and composition, creating a more demanding operating environment than a stable laboratory demonstration.

Samples analysed through an INAB-accredited laboratory returned phosphate concentrations below 0.1 mg/L P-PO4. Online analysers produced readings that closely tracked the accredited laboratory results, an important operational detail because commercial plants rely on continuous monitoring and automated process control rather than occasional manual sampling.

The facility also automatically brought ion exchange trains into and out of operation as feed flows changed. Combined with throughput above the contracted hydraulic capacity, this suggests that the control system and treatment configuration were able to respond to variable industrial conditions without losing water-quality performance.

The results provide evidence that PHOSPHIX can meet its contracted specification at full scale. They do not, however, answer every commercial question. A ten-day test cannot establish long-term resin life, maintenance frequency, plant availability, reagent consumption, hydroxyapatite handling costs or performance across multiple seasons and production cycles.

Clean TeQ Water’s next opportunity is therefore to convert the commissioning result into a longer operating record. Several months of stable operation, supported by measurable operating costs and limited unplanned downtime, would provide customers with stronger evidence than the commissioning test alone.

How could an operating European reference plant shorten Clean TeQ Water’s customer sales cycle?

Clean TeQ Water has described the reference installation as a platform for converting its European project pipeline. That expectation is commercially logical because industrial water projects often involve extended technical reviews, pilot programmes, internal capital approvals and environmental assessments before a contract is awarded.

An accessible plant in Ireland allows Clean TeQ Water and Enva to demonstrate process performance to prospective customers within the region. It may also reduce the need for every customer to begin with a lengthy pilot, although site-specific testing will remain necessary where wastewater chemistry, flow rates or discharge requirements differ materially.

Enva adds a local commercial and operational channel. The companies began their cooperation in the United Kingdom and Ireland in 2023, initially targeting several industrial water opportunities. Enva brings existing customer relationships, local project capabilities and experience in recycling and resource recovery, while Clean TeQ Water supplies the proprietary treatment platform.

The partnership model could allow Clean TeQ Water to expand without independently building a large European sales, construction and service organisation. The risk is that sales conversion will still depend on Enva’s customer access, project prioritisation and the economics of each installation. An operating reference improves credibility, but it does not automatically remove budget constraints or shorten regulatory approval processes.

The most meaningful commercial signal would be a second PHOSPHIX contract awarded partly because the customer assessed the Irish reference plant. A series of similar orders would demonstrate repeatability and allow Clean TeQ Water to standardise engineering, procurement and commissioning work rather than treating each project as a largely bespoke installation.

Does Europe’s tighter phosphorus regulation create a scalable commercial market for PHOSPHIX?

Europe’s wastewater regulation provides a supportive backdrop for technologies that remove and recover nutrients. The revised European Union Urban Wastewater Treatment Directive entered into force in January 2025 and must be transposed into national law by July 31, 2027. It introduces progressively stricter requirements for nitrogen and phosphorus removal at large urban wastewater treatment plants, with tertiary treatment applying to all plants serving agglomerations of at least 150,000 population equivalents by 2039.

The directive also encourages recovery of resources including phosphorus and nitrogen from wastewater and sludge. This aligns conceptually with PHOSPHIX because the system is intended to recover phosphate as a concentrated solid rather than transferring it into a large sludge stream.

The regulatory distinction is important. Clean TeQ Water’s completed Irish plant treats industrial pharmaceutical wastewater, while the revised directive primarily establishes rules for urban wastewater systems. The directive should therefore be viewed as a potential catalyst for Clean TeQ Water’s municipal pipeline rather than the sole legal driver for the pharmaceutical installation.

Industrial customers face separate national permits, discharge conditions and site-specific environmental requirements. Tightening industrial nutrient limits could create an additional market, particularly for manufacturers that need lower phosphate concentrations without accepting the waste volumes associated with conventional precipitation methods.

The opportunity is potentially broad, but the timing will be uneven. European Union deadlines extend over more than a decade, national implementation will vary, and municipal procurement processes are often lengthy. Clean TeQ Water may therefore see gradual pipeline growth rather than a sudden regulatory-driven order surge.

What does the PHOSPHIX milestone mean for Clean TeQ Water’s revenue quality and financial position?

The Ireland project is important because the original contract value exceeded Clean TeQ Water’s total revenue and other income of A$9.34 million for the six months ended December 31, 2025. That comparison illustrates the project’s scale relative to the company, although contract value is not equivalent to revenue recognised in a single reporting period and does not indicate the project’s final profit margin.

Clean TeQ Water reported a loss after tax of approximately A$328,000 for the half-year. During the March 2026 quarter, customer receipts reached A$4.4 million, operating cash flow was positive by A$1.1 million and the cash balance increased to A$6.8 million. The company also reported six active projects across five countries using variations of its MBIX platform.

These figures indicate that larger commercial projects are beginning to affect cash generation, but Clean TeQ Water remains a small business exposed to contract timing, working-capital movements and uneven milestone payments. Completing the PHOSPHIX plant removes execution risk associated with one major project, yet the announcement did not disclose a new order, incremental contract value or recurring revenue linked to the plant’s operation.

Revenue quality is therefore the next strategic question. Engineering and construction contracts can generate meaningful revenue but may remain lumpy and working-capital intensive. Service agreements, replacement resin sales, reagent supply, technology licensing and recurring process-support income could improve visibility and margins if Clean TeQ Water can attach them to a growing installed base.

The company has already moved in this direction elsewhere. In July 2026, it signed a long-term polymer supply and technology licence agreement for its ATA tailings dewatering technology at the Rasp Mine in New South Wales. That agreement followed a plant design and construction contract and created the potential for recurring reagent and licensing revenue once the facility is operating.

A comparable commercial structure around PHOSPHIX would strengthen the investment case. The European reference plant becomes more valuable if it leads not only to additional construction projects but also to recurring resin, technical support or licensing income across multiple sites.

How is the Clean TeQ Water share price balancing commercial validation against repeat-order risk?

The most recent reliably indexed market close before the July 28 announcement placed Clean TeQ Water shares at A$0.47 on July 24, 2026. That represented a gain of approximately 5.6% from the July 17 close of A$0.445, but a decline of about 11.3% from A$0.53 one month earlier.

With approximately 88.47 million ordinary shares on issue, the A$0.47 reference price implied a market capitalisation of roughly A$41.6 million. The stock was trading about 21.7% below its indexed 52-week high of A$0.60, while remaining 135% above the A$0.20 lower end of the range.

The share-price pattern suggests that investors have recognised improving project execution and the emergence of commercial contracts, but have not assigned an unrestricted growth valuation to the company. The market appears to be balancing the upside from scalable proprietary technologies against the risks associated with a small revenue base, project concentration and the need for continued capital discipline.

The PHOSPHIX announcement was released during the July 28 Australian trading session, meaning a reliable full-session market reaction was not yet available at the time of writing. The more meaningful sentiment test will be whether the milestone supports sustained trading interest rather than a brief announcement-driven movement.

Business News Today did not identify a widely published current broker consensus for Clean TeQ Water. In the absence of broad institutional coverage, price discovery may remain particularly sensitive to contract announcements, project completion milestones, cash-flow updates and evidence that recurring revenue is beginning to scale.

What evidence would prove PHOSPHIX is becoming a repeatable European growth platform?

The successful performance test has improved the PHOSPHIX commercial proposition. Clean TeQ Water can now show customers a full-scale plant that exceeded its contractual phosphate-removal requirement and hydraulic throughput target under variable operating conditions.

What remains unresolved is whether that performance can be replicated economically across different customers and wastewater streams. The next measurable proof point is a follow-on commercial order that uses the Ireland plant as a reference and progresses without requiring another prolonged technology-validation cycle.

Longer-term operating data will also matter. Investors and customers need evidence on uptime, resin durability, chemical consumption, labour requirements, maintenance costs and the handling or reuse economics of recovered hydroxyapatite. These variables will determine whether PHOSPHIX offers a defensible total-cost advantage over conventional treatment.

Business News Today’s assessment is that the Ireland commissioning milestone represents a genuine commercial inflection rather than another incremental pilot result. Its greatest value is not simply that phosphate concentrations were below 0.1 mg/L. It is that Clean TeQ Water has reduced the perceived adoption risk for the next customer.

The harder stage now begins. Clean TeQ Water must convert technical credibility into repeatable orders, standardised execution and higher-quality revenue. A second European PHOSPHIX contract, followed by evidence of stable operating economics at the Irish facility, would provide much stronger support for a lasting rerating than the commissioning result alone.

What are the key takeaways from Clean TeQ Water’s first European PHOSPHIX commercial plant?

• Clean TeQ Water completed commissioning and contractual performance testing of its first full-scale commercial PHOSPHIX plant in Europe.
• The Irish facility achieved phosphate concentrations below 0.1 mg/L P-PO4, more than ten times better than the 1.0 mg/L contractual requirement.
• The plant exceeded contracted hydraulic throughput and met specifications for pH, total nitrogen and chemical oxygen demand.
• PHOSPHIX is designed for approximately 99% water recovery without a liquid brine waste stream.
• The project provides Clean TeQ Water with its first operating PHOSPHIX reference and first commercial reference installation in Europe.
• The original contract was worth approximately €7 million, equivalent at announcement to more than A$11 million.
• European nutrient-removal regulation supports the addressable market, although urban and industrial wastewater rules must be distinguished.
• The reference plant may shorten customer evaluation and sales cycles, but a follow-on order is needed to prove commercial replication.
• Longer-term data on uptime, resin life, maintenance and operating costs will determine whether PHOSPHIX delivers a sustainable economic advantage.
• The central investor test is whether Clean TeQ Water can turn the installed plant into repeat contracts and recurring revenue.